EU Clinical Trial 2019-000844-81

RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF CHILDREN AND ADOLESCENTS WITH GROWTH FAILURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: AN OPEN-LABEL, MULTI-CENTER, EXTENSION STUDY  May 31, 2019

Main objective of the trial: The primary objective of this extension study is to collect safety and efficacy data on the continued use of Increlex in children and adolescents treated for primary IGFD (height Standard Deviation Score (SDS) and IGF-1 SDS <–2 and normal stimulated Growth Hormone (GH)).

Parties

Sponsors
Countries
EU US
Keywords
Increlex Mecasermin

JSON preview

Similar records

Title

Source:  EMA Last updated:  Jun 5, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.